DB pension surplus release rules are about to change the calculus for bulk annuity insurers in the UK. The government’s consultation on surplus extraction — launched on 10 June 2026, closing 2 September 2026, with draft regulations expected to come into force in April 2027 — introduces a credible run-on alternative precisely when around 4 in 5 DB schemes are in surplus, with implications for workplace pension arrangements, with an estimated aggregate of approximately £160 billion. For life insurers and reinsurers, the implications reach well beyond one year of deal flow.
Record Surplus Levels Set the Scene for the New Regime
The funding backdrop is historically unprecedented. According to the PPF 7800 index, the aggregate funding position across 4,838 UK DB schemes reached a surplus of £263.8 billion, with a funding ratio of 131.2%. The Purple Book 2025 recorded an aggregate s179 funding ratio of 125%, up from 123% in March 2024, while the buy-out basis deficit narrowed from £69.5 billion in March 2024 to £47.2 billion in March 2025. The TPR Annual Funding Statement 2026 confirmed that 80% of schemes are now in surplus on a low dependency basis, with a 124% aggregate funding level.
These numbers frame the policy context. The Pension Schemes Act 2026 received Royal Assent in April 2026, providing the statutory foundation for the new surplus flexibility framework. The DWP/HM Treasury consultation published alongside the Act sets out the detailed mechanics: trustees will be able to release surplus to sponsors or members provided the scheme is fully funded on a low dependency basis — a deliberate shift away from the more onerous buyout-level threshold that previously constrained extraction. Critically, around 60% of schemes are already in surplus on a buyout basis and around 80% on a low dependency basis, meaning the new threshold immediately activates a large cohort of schemes.
Why Run-On Competes for the Top of the Buyout Funnel
The BPA market entered 2026 on exceptional momentum. In 2025, 370 buy-ins were completed — a record, up from 307 in 2024 — generating total volumes of £38.2 billion, according to consultancy Hymans Robertson. LCP projected volumes exceeding £40 billion for the third consecutive year. Yet the composition of that activity already reflects a strategic shift: sub-£100 million buy-ins accounted for over 85% of all BPA transactions by number in H1 2025, up from 78% for the full year 2024. Large schemes were already choosing deliberate alternatives to immediate full buyout.
The surplus consultation intensifies that dynamic at the high end of the market. For a scheme with funding levels in their strongest ever financial position, the economic logic of run-on is now concrete: extract surplus today, defer insurance transfer, retain investment optionality. The low-dependency funding test is deliberately set to make this accessible rather than theoretical. Insurers seeking large buy-in mandates from well-funded UK DB schemes will face a new category of competition from trustee boards and sponsors who can now realise value without a full insurance transfer. The government acknowledges the trade-off directly: it expects buyout will remain the favoured option for employers who want to meet their obligations, but the introduction of a genuine alternative at scale changes the negotiating dynamic.
The Longevity Pipeline Gets Deferred, Not Deleted
The structural case for BPA and longevity reinsurance over the decade remains intact. TPR projects that around 2,400 to 2,600 DB schemes with £200 billion to £400 billion of assets are expected to participate in insurance transactions over the next 10 years. Schemes that choose run-on today do not exit the BPA pipeline permanently — they defer entry, typically until a trigger event (sponsor M&A, trustee governance change, longevity experience deterioration) makes transfer the path of least resistance again. Buy-out surpluses could exceed £120 billion (real) over the next decade, available for distribution to members and sponsors at the point of insurance transfer, which may itself incentivise eventual buyout by making the economics even more attractive for sponsors.
For longevity reinsurers, the pipeline of large-scheme deals simply lengthens its runway. Schemes running on generate longevity exposure that ultimately needs hedging or transferring; if they extract surplus on a low-dependency basis and manage assets internally for longer, reinsurers face a timing shift but not a loss of underlying exposure. The longevity reinsurance pipeline that has been building capacity is positioned for a market that will, over the medium term, be larger in aggregate even if near-term mega-deal frequency is dampened.
Insurer Strategy: Smaller Deals Now, Larger Books Later
The structural response for BPA insurers is already visible in the 2025 data: the pivot toward smaller, more frequent transactions. With sub-£100 million buy-ins representing over 85% of all transactions by number in H1 2025, insurers have built origination, pricing, and administration infrastructure for smaller schemes — precisely the segment least likely to be distracted by run-on optionality. The smallest schemes rarely have the governance bandwidth or sponsor appetite to operate a run-on strategy when the administrative and fiduciary burden of continued trusteeship remains constant regardless of funding level.
At the large end, the consultation’s April 2027 implementation date gives insurers a defined window. Schemes currently in advanced BPA discussions are unlikely to halt those processes for a regulatory framework that is still in draft. The risk for insurers is the cohort of large, well-funded schemes that had been considering buyout later this decade: for those schemes, run-on now becomes a credible first step. The LCP BPA market analysis attributed significant volume growth to smaller schemes; the implied message is that large-scheme supply was already constrained before run-on became policy.
